Chinese scientists say brain-computer interface technologies could reach practical public applications within several years as Beijing prioritizes the sector alongside emerging industries such as quantum computing and 6G communications.
By yourNEWS Media Newsroom
China is expanding investment and research into brain-computer interface technology as government officials and scientists say the country could begin introducing practical applications for the public within the next three to five years.
The emerging field, which allows direct communication between the human brain and computers, has been designated a priority sector in China’s latest national five-year development plan. The strategy places brain-computer interfaces among several technologies Beijing considers critical for long-term economic and scientific competitiveness, alongside quantum technologies, advanced artificial intelligence systems, next-generation telecommunications and nuclear fusion research.
Yao Dezhong, director of the Sichuan Institute of Brain Science, said technological progress and supportive policies could soon move the field beyond research laboratories.
“New policies will not change things overnight. I think after another three to five years, we will gradually see some (BCI) products moving towards actual practical service for the public,” Yao said during an interview conducted on the sidelines of China’s annual parliamentary meetings in Beijing.
China’s national strategy for the technology was introduced last year and outlines a roadmap aimed at achieving major technical breakthroughs by 2027. The plan also seeks to cultivate two or three globally competitive brain-computer interface companies by the end of the decade.
Brain-computer interface systems work by translating neural signals into digital commands that can control computers, prosthetic limbs or other devices. The technology has been explored for decades, but advances in computing power, signal processing and neuroscience have accelerated development in recent years.
China has already begun conducting human clinical trials using invasive brain-computer interface systems that require electrodes to be implanted in brain tissue. Researchers say more than ten such trials are currently underway nationwide, a number roughly comparable to the level of activity reported in the United States.
Scientists involved in the research say more than fifty patients are expected to participate in additional trials across the country this year.
Some early studies have demonstrated the potential of the technology to restore certain abilities for patients with severe physical disabilities. In recent experiments, individuals suffering from paralysis or limb loss have used brain-computer interfaces to control robotic hands or operate intelligent wheelchairs through neural signals.
Government officials have also begun integrating certain brain-computer interface treatments into medical insurance coverage in several pilot provinces, a move intended to encourage clinical development and adoption.
Analysts expect the domestic industry to grow rapidly if these technologies continue to advance. Market projections cited by Chinese consulting firm CCID estimate that the country’s brain-computer interface sector could reach 5.58 billion yuan, or approximately $809 million, by 2027.
Researchers say China holds several structural advantages in developing the technology.
“China has many advantages in BCIs, such as its huge population, enormous patient demand, cost-effective industrial chain and abundant pool of STEM talent,” Yao said.
The country’s large healthcare system also provides opportunities to conduct clinical research at scale, with many hospitals already establishing specialized laboratories dedicated to brain-computer interface studies.
Despite rapid progress, Yao acknowledged that transforming laboratory discoveries into widely available medical treatments remains a complex process.
“The path from experimental to clinical trials is quite long, and this remains a problem,” he said, noting that regulatory standards and medical testing requirements often slow the transition from research to patient use.
China’s development strategy also emphasizes the creation of national technical standards and regulatory frameworks intended to connect academic research, industrial manufacturing and clinical applications more effectively.
The country’s approach to brain-computer interface technology differs somewhat from the direction taken by several U.S. companies.
American startups such as Neuralink, founded by entrepreneur Elon Musk, have focused heavily on invasive systems in which electrodes are implanted directly into the brain using robotic surgical systems capable of inserting hundreds of microscopic electrodes within minutes.
Chinese researchers are pursuing multiple technical approaches simultaneously, including invasive, semi-invasive and non-invasive systems.
Semi-invasive devices, which are positioned on the brain’s surface rather than penetrating tissue, may produce weaker signals but can reduce surgical risks such as inflammation or long-term tissue damage.
Non-invasive devices rely on external sensors that detect neural activity through the scalp, avoiding surgery altogether but typically offering less precise signal resolution.
Yao said the surgical technology developed by Neuralink remains a significant technical achievement.
“This is a technical advantage, which I think is remarkable,” he said, referring to the robotic system used to implant electrodes.
However, he added that Chinese researchers are making rapid advances across several different types of brain-computer interface systems.
“China is actually making very fast progress in this area now,” Yao said. “In fact, Musk’s direction is basically achievable domestically.”
As competition between major technology powers intensifies, brain-computer interfaces are increasingly viewed as a strategic frontier capable of reshaping fields ranging from medicine and rehabilitation to human-machine interaction and artificial intelligence.
Chinese policymakers say continued investment, large-scale clinical testing and industry development will determine how quickly the technology moves from experimental trials to everyday use.
Original article
Comments